Journal
JOURNAL OF CELL BIOLOGY
Volume 216, Issue 3, Pages 641-656Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1083/jcb.201604025
Keywords
-
Categories
Funding
- Pershing Square Sohn Foundation
- U.S. Department of Defense [W81XWH-13-PCRP-IDA]
- American Cancer Society [RSG-14-069-01-TBE]
- National Institutes of Health [CA137050, 5P30CA045508]
- Robertson Research Fund of Cold Spring Harbor Laboratory
- National Institute of General Medical Sciences [1R01GM092900-03]
- Direct For Biological Sciences
- Div Of Biological Infrastructure [1559816] Funding Source: National Science Foundation
Ask authors/readers for more resources
Phosphatase and tensin homologue (PTEN) protein levels are critical for tumor suppression. However, the search for a recurrent cancer-associated gene alteration that causes PTEN degradation has remained futile. In this study, we show that Importin-11 (Ipo11) is a transport receptor for PTEN that is required to physically separate PTEN from elements of the PTEN degradation machinery. Mechanistically, we find that the E2 ubiquitin-conjugating enzyme and IPO11 cargo, UBE2E1, is a limiting factor for PTEN degradation. Using in vitro and in vivo gene-targeting methods, we show that Ipo11 loss results in degradation of Pten, lung adenocarcinoma, and neoplasia in mouse prostate with aberrantly high levels of Ube2e1 in the cytoplasm. These findings explain the correlation between loss of IPO11 and PTEN protein in human lung tumors. Furthermore, we find that IPO11 status predicts disease recurrence and progression to metastasis in patients choosing radical prostatectomy. Thus, our data introduce the IPO11 gene as a tumor-suppressor locus, which is of special importance in cancers that still retain at least one intact PTEN allele.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available